 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Hydroxyurea
Overview
- The Twisted Tale of Hydroxyurea, the On-Again, Off-Again HIV Drug (October 2004)
In POZ - Hydroxyurea Fact Sheet (April 1998)
From Project Inform
Research
- Literature Citations for Hydroxyurea (Regularly Updated)
From U.S. National Institutes of Health - Clinical Trials Using Hydroxyurea (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Little-Noticed Ban of Little-Used Drug Triggers Little-Known Investigation (May 2004)
Dr. Paul C. Bellman, one of the first physicians ever to treat HIV-positive patients, questions the U.S. HIV treatment guidelines' stance against hydroxyurea.
In TAGline, from Treatment Action Group - Hydroxyurea May Cut Sickle-Cell Death Rates (April 2, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Strategies to Prevent Loss of CD4+ and Onset of Resistance During Treatment Interruptions (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO - Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine and/or Hydroxyurea to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naïve HIV-1-Infected Subjects (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Hydroxyurea May Trigger Pancreatitis When Combined With Didanosine (May 2001)
In Body Positive, from Body Positive - The Effect of Hydroxyurea on Intracellular Deoxy- and Dideoxynucleoside Triphosphate Ratios in Naive Subjects Receiving ZDV, ABC, 3TC+- NVP over 48 Weeks -- CHARM Phosphorylation Substudy (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Viral Resistance Results From the International, Multicenter, Randomized, Placebo-Controlled, 48-Week Study of Hydroxyurea or Placebo Combined With Efavirenz, Didanosine and Stavudine in Treatment-Naive and -Experienced Patients (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - STOP EARTH 4 Study: Structured Treatment Interruption With or Without Hydroxyurea (January 31, 2001)
From Project Inform - Pancreatitis Associated With Hydroxyurea in Combination With Didanosine (January 13, 2001)
In British Medical Journal
  |
  |